For Healthcare Professionals

Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

clipboard-pencil

About the study

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Clinical diagnosis of HF requiring chronic treatment of loop diuretics
  2. Left Ventricular Ejection Fraction (LVEF) ≤ 40% at screening by echocardiography
  3. N-Terminal-prohormone of Brain Natriuretic Peptide (NT-proBNP) ≥400 pg/mL at screening for patients without atrial fibrillation or atrial flutter, or, NT-proBNP ≥ 1,200 pg/mL at screening for patients with atrial fibrillation or atrial flutter
  4. Treated for Heart Failure with stable, optimal pharmacological therapy
  5. Acceptable screening echocardiographic image quality

EXCLUSION CRITERIA

  1. Female patients of childbearing potential
  2. Patients with a New York Heart Association (NYHA) Class I or IV
  3. Heart failure that is clearly caused by toxin / drug such as Adriamycin
  4. Significant medical conditions or recent history suggesting the patient's study participation will potentially pose a major risk to patient's safety and well-being
  5. Need for routine scheduled outpatient IV infusions for Heart Failure or scheduled ultrafiltration
  6. History of rhabdomyolysis or history of autoimmune diseases
  7. Severe renal disease
  8. Hepatic disease
  9. Pulmonary disease limiting exercise capacity
  10. Atrial fibrillation with rapid ventricular response
  11. Life expectancy of less than 6 months
  12. Type 1 diabetes mellitus or Type 2 diabetes mellitus with very poor glycemic control
  13. Patients with anemia
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 862-259-4382Email iconEmail Study Center

Study’s details


Contition

Heart Failure,Reduced Ejection Fraction

Age

18+

Phase

Phase 2

Participants needed

200

Est. Completion Date

Jan 2023

Treatment type

Interventional


Sponsor

Innolife Co., Ltd.

ClinicalTrials.gov identifier

NCT03875183

Study number

INL1-001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.